New Eye Drug Reduces Injections for Vision Loss Patients

Millions of people facing age-related blindness may soon need fewer painful eye injections to preserve their sight.

Ocular Therapeutix announced Tuesday that their experimental drug Axpaxli maintained vision for up to a year after just one injection in patients with wet age-related macular degeneration. That's a major improvement over current treatments that require frequent doctor visits and repeated shots directly into the eye.

The Phase 3 trial delivered impressive results. At nine months, 74% of patients who received Axpaxli maintained their vision without additional treatment, compared to just 56% of patients using a low dose of Eylea, the current standard drug from Regeneron Pharma. At the one-year mark, 66% of Axpaxli patients still had stable vision versus 44% in the comparison group.

For patients with wet AMD, the most common cause of severe vision loss in older adults, this matters enormously. Current treatments work well but require injections every few weeks or months for years. Many patients struggle to keep up with the demanding schedule, and each injection comes with discomfort and infection risk.

Axpaxli's longer durability means fewer trips to the ophthalmologist and less anxiety about scheduling the next appointment. One injection potentially replacing eight to twelve could transform how people manage this chronic condition.

The Bright Side

The trial results represent more than just convenience. When patients can maintain treatment schedules more easily, they're less likely to experience vision loss from missed appointments. That could mean more seniors maintaining their independence, continuing to drive, and enjoying activities that depend on clear sight.

The drug worked by achieving the trial's primary goal of maintaining vision with extended durability. While some investors hoped for an even wider margin over existing treatments, the consistent results across both time points demonstrate real clinical benefit for patients who need it most.

Wet AMD affects approximately 1.5 million Americans, and that number grows as the population ages. Having more options that reduce treatment burden could help more patients stick with therapy and preserve their vision longer.

The results pave the way for Axpaxli to potentially join the arsenal of treatments for this sight-stealing condition, giving doctors and patients a valuable new tool.